Tissue | Expression Dynamics | Abbreviation |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ERF_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ERF_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ERF_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ERF_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00002803 | Skin | cSCC | nuclear division | 178/4864 | 439/18723 | 1.17e-11 | 5.93e-10 | 178 |
GO:005000012 | Skin | cSCC | chromosome localization | 50/4864 | 82/18723 | 2.41e-11 | 1.19e-09 | 50 |
GO:00513034 | Skin | cSCC | establishment of chromosome localization | 49/4864 | 80/18723 | 3.02e-11 | 1.48e-09 | 49 |
GO:0000723110 | Skin | cSCC | telomere maintenance | 68/4864 | 131/18723 | 1.97e-10 | 8.53e-09 | 68 |
GO:004325429 | Skin | cSCC | regulation of protein-containing complex assembly | 167/4864 | 428/18723 | 1.60e-09 | 5.97e-08 | 167 |
GO:0010639111 | Skin | cSCC | negative regulation of organelle organization | 140/4864 | 348/18723 | 3.35e-09 | 1.15e-07 | 140 |
GO:003220419 | Skin | cSCC | regulation of telomere maintenance | 45/4864 | 80/18723 | 8.82e-09 | 2.76e-07 | 45 |
GO:0043123110 | Skin | cSCC | positive regulation of I-kappaB kinase/NF-kappaB signaling | 84/4864 | 186/18723 | 1.09e-08 | 3.40e-07 | 84 |
GO:000724925 | Skin | cSCC | I-kappaB kinase/NF-kappaB signaling | 116/4864 | 281/18723 | 1.33e-08 | 4.08e-07 | 116 |
GO:004312225 | Skin | cSCC | regulation of I-kappaB kinase/NF-kappaB signaling | 105/4864 | 249/18723 | 1.70e-08 | 5.09e-07 | 105 |
GO:0007004110 | Skin | cSCC | telomere maintenance via telomerase | 40/4864 | 69/18723 | 1.83e-08 | 5.45e-07 | 40 |
GO:003150315 | Skin | cSCC | protein-containing complex localization | 95/4864 | 220/18723 | 2.00e-08 | 5.82e-07 | 95 |
GO:000626012 | Skin | cSCC | DNA replication | 106/4864 | 260/18723 | 1.18e-07 | 2.77e-06 | 106 |
GO:0010833110 | Skin | cSCC | telomere maintenance via telomere lengthening | 43/4864 | 81/18723 | 1.79e-07 | 3.94e-06 | 43 |
GO:0031334112 | Skin | cSCC | positive regulation of protein-containing complex assembly | 97/4864 | 237/18723 | 3.22e-07 | 6.51e-06 | 97 |
GO:005105217 | Skin | cSCC | regulation of DNA metabolic process | 136/4864 | 359/18723 | 3.83e-07 | 7.58e-06 | 136 |
GO:000627818 | Skin | cSCC | RNA-dependent DNA biosynthetic process | 40/4864 | 75/18723 | 4.04e-07 | 7.92e-06 | 40 |
GO:000647314 | Skin | cSCC | protein acetylation | 84/4864 | 201/18723 | 6.94e-07 | 1.29e-05 | 84 |
GO:2000278111 | Skin | cSCC | regulation of DNA biosynthetic process | 51/4864 | 106/18723 | 7.73e-07 | 1.43e-05 | 51 |
GO:004593628 | Skin | cSCC | negative regulation of phosphate metabolic process | 160/4864 | 441/18723 | 8.89e-07 | 1.63e-05 | 160 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ERF | SNV | Missense_Mutation | novel | c.260N>G | p.Tyr87Cys | p.Y87C | P50548 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-4H-AAAK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | CR |
ERF | SNV | Missense_Mutation | | c.1541N>A | p.Arg514His | p.R514H | P50548 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.511) | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ERF | SNV | Missense_Mutation | rs368169058 | c.427N>T | p.Arg143Cys | p.R143C | P50548 | protein_coding | deleterious(0) | probably_damaging(0.928) | TCGA-W8-A86G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
ERF | SNV | Missense_Mutation | | c.610N>A | p.Pro204Thr | p.P204T | P50548 | protein_coding | tolerated(0.53) | benign(0.362) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
ERF | SNV | Missense_Mutation | | c.1471N>A | p.Asp491Asn | p.D491N | P50548 | protein_coding | deleterious(0) | possibly_damaging(0.746) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
ERF | SNV | Missense_Mutation | | c.1513N>C | p.Glu505Gln | p.E505Q | P50548 | protein_coding | tolerated_low_confidence(0.79) | benign(0.014) | TCGA-EK-A2RB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ERF | SNV | Missense_Mutation | novel | c.1519G>A | p.Glu507Lys | p.E507K | P50548 | protein_coding | deleterious_low_confidence(0) | benign(0.007) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ERF | SNV | Missense_Mutation | | c.1628N>C | p.Leu543Pro | p.L543P | P50548 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.996) | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ERF | SNV | Missense_Mutation | rs767080643 | c.616N>A | p.Ala206Thr | p.A206T | P50548 | protein_coding | tolerated(0.43) | benign(0.082) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ERF | SNV | Missense_Mutation | novel | c.502N>C | p.Ser168Pro | p.S168P | P50548 | protein_coding | tolerated(0.09) | possibly_damaging(0.763) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |